Apogee Therapeutics is a clinical-stage biotechnology company focused on inflammatory and immunology (I&I) markets, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The company's pipeline includes zumilokibart (APG777), APG279 (zumilokibart + APG990), APG273 (zumilokibart + APG333), and APG808, all designed with extended half-life properties for optimized dosing. Zumilokibart's Phase 1 trial in healthy volunteers (initiated August 2023) showed a half-life of 77 days, supporting potential every threeto six-month maintenance dosing in AD. The APEX Phase 2 clinical trial for zumilokibart in moderate-to-severe AD (first patient dosed May 2024) reported positive 16-week data from Part A in July 2025. Part A of the APEX trial met its primary endpoint, showing a 71.0% reduction in Eczema Area Severity Index (EASI) score from baseline at Week 16 for zumilokibart, compared to 33.8% for placebo (p < 0.001). 66.9% of zumilokibart-treated patients achieved EASI-75, compared to 24.6% on placebo (p < 0.001), and 33.9% achieved EASI-90 compared to 14.7% on placebo (p < 0.05). Zumilokibart also demonstrated rapid and deep itch relief, with a 50.7% reduction in Itch Numeric Rating Scale (NRS) from baseline by Week 16, compared to 23.2% for placebo (p < 0.01). The safety profile of zumilokibart was favorable, with 56.1% of patients experiencing treatment-emergent adverse events (TEAEs) versus 63.4% in placebo; non-infective conjunctivitis was the most common TEAE (14.6% vs. 2.4% in placebo). APEX Phase 2 Part B enrollment was completed ahead of schedule in January 2026, exceeding target with 347 patients, testing higher and lower doses of zumilokibart. A Phase 1b trial of zumilokibart in mild-to-moderate asthma (initiated April 2025) announced positive interim data in January 2026, showing robust and durable FeNO suppression (max 60% decrease, 50% sustained through 16 weeks) with a favorable safety profile. APG990 (anti-OX40L antibody) Phase 1 trial (initiated August 2024) showed a half-life of approximately 60 days and a favorable safety profile in March 2025 interim data. APG279 (zumilokibart + APG990) Phase 1b trial against DUPIXENT in moderate-to-severe AD commenced dosing in July 2025, upsized from 50 to 80 patients. APG333 (anti-TSLP antibody) Phase 1 trial (initiated December 2024) showed a half-life of approximately 55 days and depth of suppression in key biomarkers in November 2025 interim data. APG808 (anti-IL4R antibody) Phase 1 trial (first healthy volunteers March 2024, first asthma patients September 2024) showed a half-life of approximately 55 days in December 2024 interim data. APG808 Phase 1b trial in mild-to-moderate asthma (interim results May 2025) demonstrated rapid and sustained FeNO decrease (53% max, 50% at 12 weeks) with potential for 2-month or longer maintenance dosing. The company reported a net loss of $255.8 million for the year ended December 31, 2025, and an accumulated deficit of $561.8 million. Cash, cash equivalents, and marketable securities totaled $902.9 million as of December 31, 2025, sufficient to fund operations into the second half of 2028.